Patient demographics
. | Induction . | Consolidation . |
|---|---|---|
| No. | 64 | 31* |
| Age, y (range) | 46.5 (18-59) | 46 (17-58) |
| Sex, M/F | 37/27 | 17/14 |
| De novo/secondary | 61/3 | 30/1 |
| Presenting WBC count, × 109/L (range) | 9.5 (0.54-305.8) | 9.19 (0-305.8) |
| Cytogenetic risk group, 19 favorable/standard/unfavorable/not available | 13/39/7/5 | 5/20/4/2 |
. | Induction . | Consolidation . |
|---|---|---|
| No. | 64 | 31* |
| Age, y (range) | 46.5 (18-59) | 46 (17-58) |
| Sex, M/F | 37/27 | 17/14 |
| De novo/secondary | 61/3 | 30/1 |
| Presenting WBC count, × 109/L (range) | 9.5 (0.54-305.8) | 9.19 (0-305.8) |
| Cytogenetic risk group, 19 favorable/standard/unfavorable/not available | 13/39/7/5 | 5/20/4/2 |
WBC indicates white blood cell.
A total of 23 patients were also treated with GO induction.